[197 Pages Report] The Continuous Bioprocessing Market size was estimated at USD 233.44 million in 2023 and expected to reach USD 282.42 million in 2024, at a CAGR 21.30% to reach USD 902.23 million by 2030.
Continuous bioprocessing represents a paradigm shift in the production of biopharmaceutical products, such as vaccines, monoclonal antibodies, or therapeutic proteins. Continuous bioprocessing allows for the uninterrupted flow of materials and products through the production cycle, offering potential improvements in efficiency, quality control, and scalability, unlike traditional batch processing, which processes a fixed volume of products in discrete steps. Pharmaceutical industries are advancing, and government support for the sector is the principal driver of growth for continuous bioprocessing. Increased benefits of over-batch processing & uptake of single-use technology and the continued demand for the production of biopharmaceutical products are spurring the adoption of continuous bioprocessing technologies. In contrast, high equipment costs, operational difficulties, and process change concerns pose a challenge to adopting a continuous bioprocess. In addition, regulatory considerations must be managed, as continuous bioprocessing may necessitate new validation strategies to comply with the stringent standards set by health authorities. However, several market vendors invest in research and development to address many operational challenges in the continuous bioprocessing technologies and further chart to expand the market. Moreover, the adoption of perfusion is associated with single-use equipment, and the development of a continuous bioprocessing approach to stromal cell manufacturing is expected to enhance overall market growth in the coming years significantly.
Bioreactors are vessels in which biological reactions are carried out, especially for culturing organisms such as bacteria, yeast, and mammalian cells. They are crucial for scaling up bioprocessing. Cell culture media and reagents provide the essential nutrients required for cell growth and product expression in bioprocessing. Centrifuges are utilized to separate components of a mixture based on their density. In bioprocessing, they are essential for cell clarification and product recovery. Chromatography systems are employed for the purification of biological products. Continuous chromatography technologies, including simulated moving bed (SMB) systems, offer higher productivity and better utilization of chromatography media, reducing the cost of consumables. Filtration systems are imperative for sterilizing and clarifying process fluids, warranting the removal of impurities and contaminants. Incubators and shakers are vital for optimizing growth conditions for cell cultures, providing control over temperature, humidity, and agitation. Mixing systems ensure homogeneity in bioreactors and holding tanks, influencing cell growth, nutrient distribution, and product formation consistency. In comparison, continuous bioreactors operate without interruption, ensuring consistent product quality and potentially lower manufacturing costs, and continuous centrifuges allow for the uninterrupted processing of bioproducts, enhancing efficiency and consistency.
Upstream processing, constituting the initial steps of bioproduction, involves developing and maintaining a suitable environment for the growth and multiplication of microbial cells, plant, or mammalian cells. This phase often includes media preparation, cell culture, cell preservation, and primary recovery. Downstream bioprocessing, which follows the upstream step, involves purifying these biological products, and preparing them for their final use or further formulation. Due to inherent complexity and diversity of biological products, downstream processes typically entail complex separation and purification techniques, including centrifugation, filtration, chromatography and more. Both upstream and downstream bioprocessing are critical for both productivity and quality of end products. However, they differ significantly in their chief objectives, complexities, and challenges. Upstream focuses on fostering an optimal environment for cell culture and propagation, while downstream is centered around the purification and refinement of the resultant product.
Continuous bioprocessing in cell and gene therapies involves using cutting-edge techniques to manufacture personalized treatments. This sector benefits from reduced batch-to-batch variability, enhanced scalability, and improved product consistency. Continuous processes for manufacturing monoclonal antibodies increase productivity and cost-effectiveness due to reduced labor and facility footprint and the potential for real-time quality monitoring. The vaccine industry is experiencing a growing interest in continuous bioprocessing, given the need for rapid development and deployment during pandemics and the production of seasonal vaccines, such as those for influenza. Continuous bioprocessing can substantially shorten development times and improve responsiveness to public health needs. In comparison, continuous processing offers opportunities for enhancing process intensification, stability, and throughput for vaccines.
Clinical operations are integral to continuous bioprocessing, pivotally influencing the efficacy and quality of the developed biologics. It encapsulates a broad range of activities, from early-stage clinical trials to procedures adhering to regulatory guidelines for the safety and efficacy of medicinal products. Commercial operations in continuous bioprocessing revolve around the practicality of implementing the processes on a large scale for commercialization and sale. It’s about scaling up production and ensuring consistent quality, cost-effectiveness, and regulatory compliance. While continuous bioprocessing presents a promising approach to streamline biopharmaceutical production, its implementation differs widely across the scale, clinical, and commercial operations.
Academic and research institutes often focus on fundamental science and proof-of-concept studies in continuous bioprocessing. They are crucial in advancing technology by conducting innovative research, often collaborating with industry partners. Contract development & manufacturing organizations offer outsourced development and manufacturing services to pharmaceutical and biotech companies. They are an integral part of the pharmaceutical supply chain and increasingly incorporate continuous bioprocessing to differentiate their offerings and improve cost efficiencies. Pharmaceutical and biotechnology companies are the primary end-users driving the commercial implementation of continuous bioprocessing. In comparison, academic and research institutes contribute to the continuous bioprocessing through publications, patents, and training of skilled professionals. In contrast to research institutes, CDMOs invest in scalable and adaptable technologies that can cater to multiple products and processes, optimizing time-to-market for their clients. Pharmaceutical & biotechnology companies carry out both in-house product development and commercial production, unlike academic institutes or CDMOs.
In the American region, the adoption of continuous bioprocessing is driven by a strong focus on innovation in biomanufacturing, significant investments in the biotech sector, and a regulatory environment encouraging advanced production techniques. With major pharmaceutical companies and biotech startups striving to achieve more efficient, cost-effective, and scalable manufacturing processes, continuous bioprocessing offers a competitive advantage. Additionally, the presence of a robust technological infrastructure and highly skilled workforce has facilitated the transition from traditional batch processes to continuous approaches in the Americas. Furthermore, in EMEA, high operational costs and stringent regulatory standards have pushed companies to adopt continuous bioprocessing to reduce costs and enhance the quality of biologics. The European pharmaceutical landscape is known for its strong emphasis on innovation and sustainability, which is further reflected in its rapidly growing biosimilar market, where continuous bioprocessing delivers substantial benefits in terms of production agility and speed to market. Additionally, adopting such processes is nascent in the Middle East and Africa. In this region, the continuous bioprocessing is expected to grow by the increasing need for biologics and efforts to localize pharmaceutical production capabilities. The APAC region has seen a surge in adopting continuous bioprocessing due to its rapidly expanding biopharmaceutical sector and the need to compete globally. A growing patient population needs high-quality biologics, increasing investments from players in biotechnology, and supportive government initiatives aiming to boost biomanufacturing capabilities. Several countries have demonstrated significant interest in incorporating continuous processes to accelerate drug development and production timelines, reduce manufacturing footprints, and enable cost savings, all while complying with international quality standards.
The FPNV Positioning Matrix is pivotal in evaluating the Continuous Bioprocessing Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Continuous Bioprocessing Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
WuXi Biologics Successfully Implemented a Fully Integrated Continuous Process with a Breakthrough Productivity of ~6 g/L/day at Pilot Scale
WuXi Biologics announced that it has accomplished end-to-end DS manufacturing at a pilot scale utilizing WuXiUPTM, a proprietary ultra-high productivity continuous bioprocessing platform. This well-configured bioprocess is being scaled up to GMP manufacturing and is going to be deployed across WuXi Biologics' global manufacturing sites in China, Ireland, the U.S., and Singapore. [Published On: 2023-11-22]
Sartorius and Repligen Launch Integrated Bioreactor System
Sartorius and Repligen launched an integrated bioreactor system incorporating Repligen XCell ATF upstream intensification technology into Sartorius’ Biostat STR bioreactor. According to both companies, the goal is to simplify intensified seed train and N perfusion implementation for biopharmaceutical manufacturers. [Published On: 2023-07-18]
3M To Invest Nearly USD 150 Million To Advance Capabilities In Biopharma Filtration Technology
3M company announced an investment of USD 146 million to expand its capabilities to support biotech manufacturing. This investment is going to accelerate 3M's development and delivery of vital filtration equipment developed for biological, bioprocessing, and small molecule pharmaceutical manufacturing applications, which enable biotech customers to continue to innovate therapies used for the treatment of conditions including multiple sclerosis, rheumatoid arthritis, and certain cancers. [Published On: 2023-05-31]
The report delves into recent significant developments in the Continuous Bioprocessing Market, highlighting leading vendors and their innovative profiles. These include 3D Biotek LLC, 3M Company, Adolf Kühner AG, bbi-biotech GmbH, Belach Bioteknik AB, Bio-Rad Laboratories, Inc., Bionet Servicios Técnicos S.L., Colder Products Company, Danaher Corporation, Esco Aster Pte Ltd., Esco VacciXcell, FiberCell Systems Inc., Fujifilm Holdings Corporation, GE HealthCare Technologies Inc., GEA Group, Getinge AB, Infors AG, Merck KGaA, Repligen Corporation, Sartorius AG, simAbs NV, Suzhou Transcenta Therapeutics Co., Ltd., Thermo Fisher Scientific Inc., Watson-Marlow Fluid Technology Group, and WuXi Biologics Co., Ltd..
This research report categorizes the Continuous Bioprocessing Market to forecast the revenues and analyze trends in each of the following sub-markets:
- Product
- Bioreactors
- Cell Culture Media & Reagent
- Centrifuges
- Chromatography System
- Filtration Systems
- Incubators & Shakers
- Process
- Downstream Bioprocess
- Upstream Bioprocess
- Application
- Cell & Gene Therapy
- Monoclonal Antibodies
- Vaccines
- Scale of Operation
- Clinical Operations
- Commercial Operations
- End-User
- Academic & Research Institutes
- Contract Development & Manufacturing Organizations
- Pharmaceutical & Biotechnology Companies
- Region
- Americas
- Argentina
- Brazil
- Canada
- Mexico
- United States
- California
- Florida
- Illinois
- New York
- Ohio
- Pennsylvania
- Texas
- Asia-Pacific
- Australia
- China
- India
- Indonesia
- Japan
- Malaysia
- Philippines
- Singapore
- South Korea
- Taiwan
- Thailand
- Vietnam
- Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom
- Americas
- Market Penetration: It presents comprehensive information on the market provided by key players.
- Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
- Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
- Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
- Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
- What is the market size and forecast of the Continuous Bioprocessing Market?
- Which products, segments, applications, and areas should one consider investing in over the forecast period in the Continuous Bioprocessing Market?
- What are the technology trends and regulatory frameworks in the Continuous Bioprocessing Market?
- What is the market share of the leading vendors in the Continuous Bioprocessing Market?
- Which modes and strategic moves are suitable for entering the Continuous Bioprocessing Market?
- Preface
- Research Methodology
- Executive Summary
- Market Overview
- Market Insights
- Continuous Bioprocessing Market, by Product
- Continuous Bioprocessing Market, by Process
- Continuous Bioprocessing Market, by Application
- Continuous Bioprocessing Market, by Scale of Operation
- Continuous Bioprocessing Market, by End-User
- Americas Continuous Bioprocessing Market
- Asia-Pacific Continuous Bioprocessing Market
- Europe, Middle East & Africa Continuous Bioprocessing Market
- Competitive Landscape
- Competitive Portfolio
- List of Figures [Total: 26]
- List of Tables [Total: 468]
- List of Companies Mentioned [Total: 25]
The key drivers behind continuous bioprocessing:
Continuous bioprocessing is being driven by several factors. The primary driver is the need for more efficient, streamlined biologics production. Continuous bioprocessing allows for faster product development, cheaper process development, and optimal utilization of resources. Moreover, it ensures consistent product quality, reduces batch-to-batch variability, and enables real-time monitoring and control of the process, thereby minimizing the risk of contamination.
Benefits of automation and digitization in continuous bioprocessing:
The use of automation and digitization is crucial in continuous bioprocessing. It accelerates the process, reduces the risk of human error, and boosts product quality and consistency. By leveraging analytics, machine learning, and robotics, biopharmaceutical companies can handle data more effectively, monitor production efficiency, and optimize operational processes in real-time. This ultimately reduces production costs, accelerates time-to-market, and enhances customer satisfaction.
Challenges facing continuous bioprocessing:
Despite the advantages of continuous bioprocessing, there are still challenges that need to be addressed. For example, the lack of standardization, validated processes, and technology transfer protocols remain a significant barrier to widespread adoption. The scaling-up of processes from laboratory to commercial scale still poses challenges due to differences in equipment and process conditions. Moreover, the high cost of equipment, tech support, and regulatory compliance, along with the complex regulatory requirements, hinders adoption and limits entry for smaller start-up companies.
The potential impact of continuous bioprocessing:
Continuous bioprocessing has the potential to revolutionize the biotechnology industry. It ensures faster, more streamlined production of high-quality biologics by providing more accurate, timely data. Furthermore, it offers biopharmaceutical companies the ability to adjust their processes to improve efficiency, reduce costs, and improve product quality. On a larger scale, it enables the biotechnology industry to respond to global health challenges, such as the COVID-19 pandemic, by enabling fast, efficient production of life-saving therapeutics and vaccines.
The trend toward automation and digitization in continuous bioprocessing is essential to ensure the industry's growth and innovation in the future. However, to unlock this potential, biopharmaceutical companies must be willing to invest in technology, regulatory compliance, and process standardization. Companies must embrace innovation and digitization to stay competitive in the age of Industry 4.0.
- How big is the Continuous Bioprocessing Market?
- What is the Continuous Bioprocessing Market growth?
- When do I get the report?
- In what format does this report get delivered to me?
- How long has 360iResearch been around?
- What if I have a question about your reports?
- Can I share this report with my team?
- Can I use your research in my presentation?